financetom
Business
financetom
/
Business
/
EU dismisses reports that it is ready to accept flat 10% U.S. tariff
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EU dismisses reports that it is ready to accept flat 10% U.S. tariff
Jun 16, 2025 9:37 AM

BRUSSELS (Reuters) -The European Commission dismissed on Monday reports suggesting it was willing to accept a broad U.S. tariff of 10% on EU goods as speculative and said they did not reflect current discussions.

"Negotiations are ongoing, and no agreement has been reached at this stage. The EU has from the start objected to unjustified and illegal U.S. tariffs," the Commission said in a statement.

German newspaper Handelsblatt had said earlier on Monday that Brussels negotiators were prepared to accept the flat 10% U.S. tariff on most EU imports to avert higher duties on EU cars, drugs and electronics.

The Commission, which negotiates trade deals for the 27-nation EU, responded by saying "reports suggesting that the EU accepts a US tariff of 10% across all our exports are speculative and do not reflect the current state of discussions."

The next step in negotiations is a planned meeting between European Trade Commissioner Maros Sefcovic and U.S. Trade Representative Jamieson Greer at this week's G7 meeting in Canada.

U.S. President Donald Trump has announced wide-ranging tariffs on trade partners, and wants to reduce the U.S. goods trade deficit with the EU, which he has said was "formed in order to screw the United States".

European Union exporters are currently contending with U.S. tariffs of 50% for steel and aluminium, 25% for cars and car parts and a 10% tariff on most other goods, which could rise in July after a 90-day pause announced by Trump in early April.

Britain accepted a limited bilateral trade agreement in May that retains Trump's 10% tariffs on British exports, while cutting higher rates for steel and cars. EU trade ministers subsequently said that would not be acceptable for the 27-nation bloc.

However, U.S. officials have said in public and told EU counterparts in private that the 10% flat rate is a minimum it will not drop below for any trading partner.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TeraWulf Q3 Loss Widens, Revenue Rises
TeraWulf Q3 Loss Widens, Revenue Rises
Nov 10, 2025
04:33 PM EST, 11/10/2025 (MT Newswires) -- TeraWulf ( WULF ) reported a Q3 loss late Monday of $1.13 per diluted share, widening from a loss of $0.06 a year earlier. Analysts surveyed by FactSet expected a loss of $0.04. Revenue for the three months ended Sept. 30 was $50.6 million, up from $27.1 million a year earlier. Analysts polled...
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Nov 10, 2025
Overview * Theravance Q3 revenue slightly beats estimates, driven by Viatris collaboration * Adjusted net income for Q3 beats estimates, reflecting financial discipline * YUPELRI net sales in Q3 reach $71.4 mln, up 15% YoY Outlook * Theravance expects topline Phase 3 CYPRESS results in Q1 2026 * Company on track to achieve $50 mln TRELEGY sales milestone in 2025...
StandardAero Q3 Earnings, Revenue Rise
StandardAero Q3 Earnings, Revenue Rise
Nov 10, 2025
04:33 PM EST, 11/10/2025 (MT Newswires) -- StandardAero ( SARO ) reported Q3 earnings late Monday of $0.20 per diluted share, up from $0.06 a year earlier. Analysts polled by FactSet expected $0.20. Revenue in the three months ended Sept. 30 rose to $1.5 billion from $1.24 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion. The company...
Cell therapy firm ProKidney's Q3 net loss narrows 
Cell therapy firm ProKidney's Q3 net loss narrows 
Nov 10, 2025
Overview * ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027 Outlook * Company expects cash to support operations into mid-2027 Result Drivers * R&D EXPENSES - Decrease in R&D expenses due to winding down of completed or terminated trials Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 $38.76 Operatin mln g Expenses Q3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved